Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017)

Jorgensen K. K.; Olsen I. C.; Goll G. L.

首页> 外文期刊>The Lancet >Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017)

【24h】

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017)

机译：从发起者infliximab转换为生物仿制物CT-P13与发起者incriximab（NOR-SWITCH）的维护治疗相比：52周，随机，双盲，非劣势试验（Vol 389，PG 2304,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2017年第10086期|共1页
作者
Jorgensen K. K.; Olsen I. C.; Goll G. L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017) [J] . Jorgensen K. K., Olsen I. C., Goll G. L. The Lancet . 2017,第10086期

机译：从发起者infliximab转换为生物仿制物CT-P13与发起者incriximab（NOR-SWITCH）的维护治疗相比：52周，随机，双盲，非劣势试验（Vol 389，PG 2304,2017）
2. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J] . Jorgensen Kristin K., Olsen Inge C., Goll Guro L., The Lancet . 2017,第10086期

机译：与发芽治疗的发起者英美昔单抗切换到生物仿制物CT-P13与发起者英夫利昔单抗（NOR-SWITCH）的治疗相比：52周，随机，双盲，非劣势试验
3. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study [J] . Ye Byong Duk, Pesegova Marina, Alexeeva Olga, The Lancet . 2019,第10182期

机译：生物仿制性CT-P13的疗效和安全性与患有活跃的Crohn疾病患者的发起者英夫利昔单抗：国际，随机，双盲，第3期非劣级研究
4. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab [O] . Timothy Fitzgerald, Richard Melsheimer, Marie-Hélène Lafeuille, 2021

机译：患者稳定的转换和停止模式均发芽的英夫利昔单抗他们切换到英夫利昔单抗或留在发起者infliximab上
5. DOP062 Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial [O] . K.K. Jørgensen, I.C. Olsen, G.L. Goll, 2017

机译：DOP062 BioSimilar Flowiximab（CT-P13）不逊于发起者Infliximab：来自Nor-Switch试验的Crohn病和溃疡性结肠炎的探索性IBD亚组分析

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017)

著录项

相似文献

相关主题

期刊订阅